Sensitivity testing of ceftriaxone;Empfindlichkeitsspektrum von Ceftriaxon und anderen Antibiotika: Retrospektive Untersuchungen zu den Jahren 1992 bis 1996

Krankenhauspharmazie

Volumn 18, Issue 11, 1997, Pages 531-533

  Focht, Josef ^a   Nösner, Kristoff ^a  

^a Bioscientia Center for Human Genetics   (Germany)

Author keywords

Ceftriaxone; Resistance; Sensitivity testing

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFOTIAM; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CLAVULANIC ACID; MEZLOCILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; SULTAMICILLIN; TAZOBACTAM;

ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; NONHUMAN;

EID: 0030709215     PISSN: 01737597     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Abraham EP, Newton GGF. The Structure of Cephalosporin. C Biochem J 1961;79:377-93.
2. Normenausschuß Medizia (NAMed) im Deutschen Institut für Normung e. V. (DIN). Methoden zur Empfindlichkeitsprüfung von bakteriellen Krankheitserregern (außer Mykobakterien) gegen Chemotherapeutika. Beiblatt 1 zu DIN 58940, 2. Auflage. Berlin: Beuth-Verlag, 1992.
3. DIN-Taschenbuch 222. Medizinische Mikrobiologie und Immunologie. Berlin: Beuth-Verlag, 1992.
4. Edwards DJ, Stoeckel K. The pharmacokinetics of new oral cephalosporins in children. Chemotherapy 1992;38(Suppl 2):2-9.
5. Fass RJ, Prior RB. Comparative in vitro activities of Piperacillin-Tazobactam and Ticarcillin-Clavulanate. Antimicrob Agents Chemother 1989;33:1268-74.
6. Focht J, Rolinson GN, Johnsen J. Sensitivity of clinical isolates from German hospitals to Amoxicillin/Clavulanic acid (Augmentin) compared with other antibiotics. Chemotherapy 1988;34:322-41.
7. Focht J, Nösner K. Empfindlichkeitsspektrum von Ceftriaxon und anderen Antibiotika. Retrospektive Untersuchungen zu den Jahren 1935-1993. Krankenhauspharmazie 1994;12:683-5.
8. Frenkel LD, and the Multicenter Cefiriaxone Pediatric Study Group. Once-daily administration of ceftriaxone for the treatment of selected serious bacterial infections in children. Pediatrics 1988;82:486.
9. Grimm H. Methodische Besonderheiten der Testung von Tazobactam/Piperacillin (Tazobac). In: Adam D, Stille W, Hisg. Tazobactam/Piperacillin. FAC 11-4. Fortschr Antimikrob Antineoplast Chemother. München: Futuramed Verlag, 1992:389-98.
10. Higham M, Cunningham FM, Teele DW. Ceftriaxone administered once or twice a day for treatment of bacterial infections of childhood. Pediatr Infect Dis 1985;4:22.
11. Karachalios GN, Georgiopoulos AN, Kanatakis S. Treatment of various infections in an outpatient practice by intramuscular ceftriaxone: home parenteral therapy. Chemotherapy 1989;35:389-92.
12. Kliebe C, Nies BA, Meyer JF, Tolxdorff-Neutzling RM, et al. Evolution of the plasmid coded resistance to third generation cephalosporins. Antimicrob Agents Chemother 1985;28:302-7.
13. Kliebe C, Nies B, Meyer JF, et al. Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1985;28:302-7.
14. Knothe H, Shah P, Kremery V, Antal M, et al. Transferable resistance to cefotaxime, cefoxitin, cefamandole, and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983;6.315-7.
15. Kuck NA, Jacobus NV, Petersen PJ, Weiss WJ, et al. Comparative in vitro and in vivo activities of Piperacillin combined with the β-lactamase inhibitors Tazobactam, Clavulanic Acid, and Sulbactam. Antimicrob Agents Chemother 1989;33:1964-9.
16. Moellering RC Jr, Sentochnik DE. Cephalosporins. In: Gorbach SL, Bartlett IG, Blaclow NR, editors. Philadelphia: WB Saunders, 1992:172-82.
17. Neu HC. The pharmacokinetics of new cephalosporins: significance in clinical practice. Bull New York Acad Med 1984;60:327-39.
18. Nicolle LE. Prior antimicrobial therapy and resistance of Enterobacter, Citrobacter and Serratia to third generation cephalosporins. J Hosp Infect 1988; 11:321-7.